Key Highlights

  • 13.9 million is the USD record Revenue SS Innovations International, Inc. (NASDAQ:SSII) reported for the second quarter of 2026, up 39.4% from USD 10.0 million, while the gross Margin eased to 50.9% from 59.1%.
  • 30 SSi Mantra surgical robotic systems were installed in the second quarter of 2026, up 30.4%, lifting the cumulative installed base to 224 systems across twelve countries.
  • 2.7 million is the USD net loss for the second quarter of 2026, or USD 0.01 per diluted share, compared with a net loss of USD 0.3 million in the prior-year quarter.
  • 13.6 million is the USD cash balance, excluding restricted cash, on June 30, 2026, with no long-term debt, and the company has not issued numeric guidance for the remainder of the year.

What Investors Expect From SS Innovations International, Inc. (NASDAQ:SSII) on November 16, 2026

The surgical robotics company is scheduled to report third quarter 2026 results on November 16, 2026. Investors will compare the update with a second quarter in which revenue reached a record USD 13.9 million and first-half revenue rose 65.6% to USD 25.0 million from USD 15.1 million. System sales contributed USD 12.4 million in the quarter and USD 21.9 million in the half. Gross Profit for the quarter was USD 7.1 million, an increase of 20.0%, which trailed the pace of revenue growth.

The Rationale: Last Reported Quarter and Management Outlook for SS Innovations International, Inc. (NASDAQ:SSII)

Installations totaled 56 in the first half, up 47.4%, and surgeries performed on the platform reached 2,528 in the second quarter and 4,387 in the half, for a cumulative 12,272 including 175 telesurgeries, 637 cardiac and 222 pediatric procedures. On regulation, the 510(k) premarket notification for the SSi Mantra is under FDA review, and management expects the review to conclude by the end of the first quarter of 2027. Management believes EU CE marking can be obtained by the end of 2026.

Valuation, Liquidity and Risks for SS Innovations International, Inc. (NASDAQ:SSII)

The first-half net loss was USD 6.2 million, or USD 0.03 per share, compared with USD 5.9 million. Restricted cash was USD 8.6 million current and USD 0.4 million non-current, and deferred revenue was USD 3.9 million current and USD 8.7 million non-current. There were 200,169,035 common shares outstanding on June 30, 2026, and weighted diluted shares were 209.4 million for the quarter. Risks include the timing of FDA and CE decisions, margin compression, reliance on system placements, and the absence of disclosed orders or backlog.

Where Things Stand

SS Innovations International, Inc. (NASDAQ:SSII) reports on November 16, 2026 with revenue momentum and regulatory milestones in focus. The company has grown first-half revenue to USD 25.0 million, expanded its installed base to 224 systems and holds USD 13.6 million of unrestricted cash with no long-term debt. Investors will look for the pace of third quarter installations after 30 in the second quarter, whether the gross margin recovers from 50.9%, any update on the FDA 510(k) review targeted to conclude by the end of the first quarter of 2027, and progress toward CE marking by the end of 2026.